Latest news
25 items- SECSEC Form 8-K filed by 23andMe Holding Co.8-K - 23andMe Holding Co. (0001804591) (Filer)
- PR23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable LawSAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"
- INSIDERSEC Form 3 filed by new insider Kvarda Matthew3 - 23andMe Holding Co. (0001804591) (Issuer)
- INSIDERSEC Form 3 filed by new insider Walper Thomas B.3 - 23andMe Holding Co. (0001804591) (Issuer)
- SEC23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure8-K - 23andMe Holding Co. (0001804591) (Filer)
- PR23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale ProcessIntends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (
- PR23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab TestSAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process
- PR23andMe Special Committee Rejects Acquisition Proposal From CEO Anne WojcickiSUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to "roll over" their current equity ownership) for cash consideration of $0.41 per share. Ms. Wojcicki's proposal, which was included in an amended Schedule 13D filing made by Ms. Wojcicki with the Securities and Exchan
- INSIDERChief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)4 - 23andMe Holding Co. (0001804591) (Issuer)
- SECSEC Form 10-Q filed by 23andMe Holding Co.10-Q - 23andMe Holding Co. (0001804591) (Filer)
- PR23andMe Launches New Genetic Report on OsteoporosisSUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new polygenic risk score (PRS) report* on the genetics of osteoporosis for 23andMe+ Premium members. The report informs customers if they are at a higher likelihood of developing osteoporosis based on a statistical model developed by 23andMe through its proprietary research database, along with actionable lifestyle factors that can reduce their risk. Osteoporosis is a condition in which bone density becomes too low, which makes bones more fragile and prone to breaks (frac
- PR23andMe Special Committee Announces Exploration of Strategic AlternativesSUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (NASDAQ:ME) ("23andMe" or the "Company"), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a possible sale of the company, business combination, sale of all or part of the Company's assets, licensing of assets, restructuring, or other strategic action. The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review
- SEC23andMe Holding Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 23andMe Holding Co. (0001804591) (Filer)
- PR23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted TechnologySUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world's leading biomedical research organizations and governments. Discover23 provides analysis-ready genome-wide association studies (GWAS) conducted on 1000+ disease and condition cohorts curated from 4.7B phenotypic data points by 23andMe's expert scientists. Biopharma collabo
- INSIDERChief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,279 shares, decreasing direct ownership by 5% to 102,122 units (SEC Form 4)4 - 23andMe Holding Co. (0001804591) (Issuer)
- PR23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & InflammationSUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine. The 23andMe genetic and phenotypic healt
- 13D/GAmendment: SEC Form SC 13D/A filed by 23andMe Holding Co.SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)
- 13D/GAmendment: SEC Form SC 13D/A filed by 23andMe Holding Co.SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)
- SECSEC Form 144 filed by 23andMe Holding Co.144 - 23andMe Holding Co. (0001804591) (Subject)
- 13D/GSEC Form SC 13G filed by 23andMe Holding Co.SC 13G - 23andMe Holding Co. (0001804591) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by 23andMe Holding Co.SC 13G/A - 23andMe Holding Co. (0001804591) (Subject)
- SECSEC Form 10-Q filed by 23andMe Holding Co.10-Q - 23andMe Holding Co. (0001804591) (Filer)
- PR23andMe Reports Second Quarter Fiscal Year 2025 Financial ResultsSUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p
- PR23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the FutureReduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing further development of all its therapeutics programs, while evaluating strategic alternatives for its clinical and preclinical assets. The Company is reducing its overall headcou
- PRCORRECTION - 23andMe to Report Q2 FY2025 Financial ResultsSUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23
ME FAQ
6 questionsWhat does 23andMe Holding Co. do?
23andMe Holding Co. operates as a consumer genetics and research company. The company provides a crowdsourced platform for genetic research. Its platform has generated various publications on the genetic underpinnings of a range of diseases, conditions, and traits, as well as enables it in pursuing drug discovery programs rooted in human genetics across various disease areas, including oncology, respiratory, and cardiovascular diseases, as well as other therapeutic areas. The company was founded in 2006 and is based in Sunnyvale, California.Where does ME stock trade?
23andMe Holding Co. (ME) is listed on NASDAQ.What sector and industry is ME in?
23andMe Holding Co. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ME?
23andMe Holding Co. has had 8 recent analyst actions on file. The most recent action was from Berenberg: Buy with a $700.00 price target on 2022-11-29. Recent price targets range from $600.00 to $1400.00.What companies are similar to ME?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ME side-by-side with any of them on Quantisnow.How can I track ME on Quantisnow?
Quantisnow aggregates 23andMe Holding Co.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ME to receive live email and push alerts on every new disclosure.